PAM
CBAY

Panagora Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Panagora Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-960
Closed -$4K – 2999
2021
Q1 		$4K Hold
960
– – ﹤0.01% 2633
2020
Q4 		$6K Buy
+960
New +$7.27K ﹤0.01% 2437
2020
Q2 		– Sell
-22,227
Closed -$33K – 2676
2020
Q1 		$33K Hold
22,227
– – ﹤0.01% 1975
2019
Q4 		$44K Buy
+22,227
New +$83.5K ﹤0.01% 1947
2018
Q2 		– Sell
-4,084
Closed -$53K – 2432
2018
Q1 		$53K Buy
+4,084
New +$50.7K ﹤0.01% 2015

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Panagora Asset Management's CBAY Position: Q2 2021 in Review

Panagora Asset Management sold out of Cymabay Therapeutics (CBAY) in Q2 2021, closing a stake of 960 shares — an estimated $4K sold.

Panagora Asset Management first reported a position in CBAY in Q1 2018 and held it in 5 quarters. The position peaked at $53K in Q1 2018. 113 funds tracked by Wall St. Rank hold CBAY as of Q2 2021.

  • Panagora Asset Management reported no remaining Cymabay Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Panagora Asset Management sold 960 Cymabay Therapeutics shares in Q2 2021, an estimated $4K.
  • Panagora Asset Management first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 5 quarters.
  • Panagora Asset Management's Cymabay Therapeutics position peaked at $53K in Q1 2018.
  • 113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2021.

Based on Panagora Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.